PMID
Data
Article Title
Citation
Organization
Deposition
Files Download
-
3-triazolyl methyl-1,3,5-triazine-2,4-dione compounds and preparation method and application thereof

US Patent US11612603 (2023)
SHAANXI PANLONG PHARMACEUTICAL CO., LTD.
05/09/23
-
Protacs targeting coronavirus 3CL protease and preparation method and application thereof

US Patent US11530195 (2022)
SHAANXI PANLONG PHARMACEUTICAL CO., LTD.
02/16/23
-
Protacs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereof

US Patent US11518759 (2022)
SHAANXI PANLONG PHARMACEUTICAL CO., LTD.
02/05/23
-
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES

WIPO WO2022224223 (2022)
NOVARTIS AG
01/31/23
-
CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAME

WIPO WO2023004291 (2023)
BAYLOR COLLEGE OF MEDICINE
01/31/23
-
ETHER-LINKED ANTIVIRAL COMPOUNDS

WIPO WO2022208262 (2022)
PFIZER INC.
01/31/23
-
SARS-COV-2 MPRO INHIBITOR COMPOUNDS

WIPO WO2022129953 (2022)
HEPTARES THERAPEUTICS LIMITED
10/05/22
-
Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.

Eur J Med Chem 223: (2021)
Chinese Academy of Medical Science and Peking Union Medical College
08/23/22
-
Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.

Bioorg Med Chem Lett 43: (2021)
Bristol University
08/20/22
-
Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors.

Bioorg Med Chem Lett 50: (2021)
Australian National University
08/19/22
-
Inhibitors of cysteine proteases and methods of use thereof

US Patent US11312704 (2022)
Pardes Biosciences, Inc.
08/06/22
-
ANTIVIRAL HETEROARYL KETONE DERIVATIVES

WIPO WO2022013684 (2022)
PFIZER INC.
06/09/22
-
NOVEL CORONAVIRUS MAIN PROTEASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

WIPO WO2022021841 (2022)
SICHUAN UNIVERSITY
06/09/22
-
Potent Inhibition of SARS-CoV-2 nsp14

J Med Chem 65: 6231-6249 (2022)
University of Montpellier
05/17/22
-
Aminocarbamoyl compounds for the treatment of viral infections

WIPO WO2022043374 (2022)
F. Hoffmann-La Roche Ag
03/30/22
-
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.

Nature (2022)
University of British Columbia
03/30/22
-
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

J Med Chem 63: 13205-13227 (2020)
South China Agricultural University
03/27/22
-
Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

bioRxiv 2022: (2022)
Shionogi Pharmaceutical Research Center
02/02/22
-
Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infections

WIPO WO2021219089 (2021)
Insilico Medicine Ip Limited
01/27/22
-
Perspectives on SARS-CoV-2 Main Protease Inhibitors.

J Med Chem 64: 16922-16955 (2021)
Michigan State University
01/27/22
-
Inhibitors of cysteine proteases and methods of use thereof

US Patent US11124497 (2021)
Pardes Biosciences, Inc.
01/13/22
-
Compounds and method of treating covid-19

WIPO WO2021205290 (2021)
Pfizer Inc.
01/13/22
-
Compounds and methods for the treatment of covid-19

WIPO WO2021205298 (2021)
Pfizer Inc.
01/13/22
-
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.

J Am Chem Soc 143: 20697-20709 (2021)
The University of Arizona
01/13/22
-
Nitrile-containing antiviral compounds

WIPO WO2021250648 (2021)
Pfizer Inc.
01/13/22
-
Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.

J Med Chem (2021)
University of Illinois at Chicago
11/05/21
-
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.

J Med Chem 64: 14702-14714 (2021)
Purdue University
11/05/21
-
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Science 374: 1-13 (2021)
Pfizer
11/05/21
-
A patent review on SARS coronavirus main protease (3CLpro) inhibitors.

ChemMedChem (2021)
Experimental Drug Development Centre
11/05/21
-
Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics

bioRxiv 2021: (2021)
Israel Institution of Biological Research
11/05/21
-
DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 M

Proc Natl Acad Sci U S A 118: (2021)
Baylor College of Medicine
09/11/21
-
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.

ACS Med Chem Lett 12: 1325-1332 (2021)
Yale University
09/10/21
-
Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.

ACS Pharmacol Transl Sci 4: 1408-1421 (2021)
The University of Arizona
09/10/21
-
Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL

J Med Chem 64: (2021)
Cleveland Clinic
08/14/21
-
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.

J Med Chem 63: 7491-7507 (2020)
Qpex Biopharma, Inc.
08/13/21
-
Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease.

J Med Chem 64: 10047-10058 (2021)
Wichita State University
07/29/21
-
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.

Bioorg Med Chem Lett 48: 128263 (2021)
A*STAR
07/29/21
-
Peptidomimetic ?-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and

J Med Chem (2021)
University of Alberta
07/29/21
-
Highly active compounds against COVID-19

US Patent US10874687 (2020)
Atea Pharmaceuticals, Inc.
07/25/21
-
N4-hydroxycytidine and derivatives and anti-viral uses related thereto

US Patent US10874683 (2020)
Emory University
07/25/21
-
SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model

Science (2021)
Sichuan University
02/28/21
-
Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

ACS Cent Sci (2021)
Yale University
02/28/21
-
Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling.

Bioorg Med Chem 27: 1981-1989 (2019)
University of Illinois at Chicago
02/24/21
-
The Other Angiotensin II Receptor: AT

J Med Chem 63: 1978-1995 (2020)
Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL)
02/21/21
-
Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen

bioRxiv 2020: (2020)
Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) and Fraunhofer Cluster of Excellence for Immune mediated diseases (CIMD)
01/31/21
-
Inhibition of SARS-CoV-2 main protease by allosteric drug-binding

bioRxiv 2020: (2020)
Center for Free-Electron Laser Science
01/31/21
-
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

ChemMedChem (2020)
Texas A&M University
01/31/21
-
Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis

WIPO WO2006061714 (2006)
Pfizer Inc.
01/31/21
-
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.

Sci Transl Med 12: 1-15 (2020)
University of North Carolina at Chapel Hill
11/13/20
-
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.

Antimicrob Agents Chemother 64: (2020)
Institut Pasteur Korea
11/13/20
-
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.

Med Res Rev (2020)
University of Bonn
11/07/20
-
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.

J Med Chem 59: 6595-628 (2016)
University of Bonn
11/07/20
-
Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis

WIPO WO2005113580 (2005)
Pfizer Inc.
10/17/20
-
Broad-spectrum non-covalent coronavirus protease inhibitors

US Patent US9975885 (2018)
PURDUE RESEARCH FOUNDATION
09/25/20
-
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.

bioRxiv (2020)
National Institutes of Health
09/21/20
-
Discovery of potent inhibitors of PLproCoV2 by screening a library of selenium-containing compounds

bioRxiv 1-12 (2020)
University ofAmsterdam
09/21/20
-
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors.

Science 368: 409-412 (2020)
University of Lubeck
09/21/20
-
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.

Science 368: 1331-1335 (2020)
Shanghai Institute of Materia Medica
09/21/20
-
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19.

bioRxiv (2020)
Pfizer Inc.
09/21/20
-
Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.

ACS Infect Dis 6: 2099-2109 (2020)
University of Georgia
09/21/20
-
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

Cancer Discov 4: 1310-25 (2014)
Fred Hutchinson Cancer Research Center
09/21/20
-
Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.

Biochem Biophys Res Commun 333: 194-9 (2005)
National Taiwan University
09/21/20
-
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Nature 582: 289-293 (2020)
ShanghaiTech University
09/06/20
-
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.

Sci Transl Med 12: (2020)
Wichita State University
09/06/20
-
Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.

Bioorg Med Chem 22: 292-302 (2014)
Tianjin University of Science and Technology
09/02/20
-
Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings.

Bioorg Med Chem 22: 167-77 (2014)
University of Illinois at Chicago
09/02/20
-
Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.

Bioorg Med Chem 21: 3730-7 (2013)
Korea Research Institute of Bioscience and Biotechnology
09/01/20
-
Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.

Bioorg Med Chem Lett 23: 6317-20 (2013)
Kansas State University
09/01/20
-
Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases.

Eur J Med Chem 59: 1-6 (2013)
The Chinese University of Hong Kong
08/31/20
-
Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.

Bioorg Med Chem 18: 7849-54 (2010)
Academia Sinica
08/28/20
-
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.

Bioorg Med Chem 18: 7940-7 (2010)
Korea Research Institute of Bioscience and Biotechnology
08/28/20
-
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.

Bioorg Med Chem 17: 5139-45 (2009)
National Human Genome Research Institute
08/27/20
-
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.

Bioorg Med Chem Lett 20: 1873-6 (2010)
Korea Research Institute of Bioscience and Biotechnology
08/27/20
-
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.

Bioorg Med Chem Lett 19: 2722-7 (2009)
Kyoto Pharmaceutical University
08/27/20
-
Novel small-molecule inhibitors of transmissible gastroenteritis virus.

Antimicrob Agents Chemother 51: 3924-31 (2007)
National Health Research Institute
08/27/20
-
Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.

Bioorg Med Chem Lett 17: 5876-80 (2007)
Purdue University
08/24/20
-
Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.

Eur J Med Chem 150: 334-346 (2018)
Wichita State University
08/16/20
-
Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.

Bioorg Med Chem 24: 3035-3042 (2016)
Academia Sinica
09/14/17
-
Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia.

J Enzyme Inhib Med Chem 29: 59-63 (2014)
Gyeongsang National University
08/28/17
-
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.

ACS Chem Biol 10: 1456-65 (2015)
University of Illinois at Chicago
10/15/15
-
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.

Eur J Med Chem 79: 184-93 (2014)
University of Lille
02/07/15
-
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.

Bioorg Med Chem Lett 18: 732-7 (2008)
GlaxoSmithKline
05/21/13
-
Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.

Bioorg Med Chem 20: 5928-35 (2012)
Korea Research Institute of Bioscience and Biotechnology
05/17/13
-
Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.

J Biol Chem 284: 7646-55 (2009)
National Yang-Ming University
10/29/12
-
Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.

Bioorg Med Chem Lett 21: 4860-4 (2011)
Philipps University Marburg
03/23/12
-
Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.

Bioorg Med Chem Lett 21: 3088-91 (2011)
Chonnam National University
12/04/11
-
Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.

Chem Biol 13: 261-8 (2006)
Academia Sinica
07/07/11
-
Phage-encoded combinatorial chemical libraries based on bicyclic peptides.

Nat Chem Biol 5: 502-7 (2009)
Laboratory of Molecular Biology, Medical Research Council
06/10/11
-
Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives.

Bioorg Med Chem Lett 19: 4538-41 (2009)
Konkuk University
08/27/10
-
Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase.

Bioorg Med Chem Lett 19: 1636-8 (2009)
Konkuk University
01/11/10
-
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.

Bioorg Med Chem Lett 18: 1681-7 (2008)
GlaxoSmithKline
11/11/09
-
Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors.

J Med Chem 48: 6767-71 (2005)
Purdue University
11/10/09
-
Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.

J Med Chem 50: 1850-64 (2007)
University of Alberta
11/10/09
-
Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.

J Med Chem 49: 3440-3 (2006)
Peking University
11/10/09
-
Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.

Bioorg Med Chem Lett 15: 3058-62 (2005)
Development Center for Biotechnology
11/10/09
-
Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease.

J Med Chem 52: 5228-40 (2009)
Purdue University
09/14/09
-
Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits.

Bioorg Med Chem 16: 4138-49 (2008)
University of Mississippi
07/08/08
-
Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.

J Med Chem 49: 3485-95 (2006)
National Tsing Hua University
09/26/06
-
Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.

Bioorg Med Chem 13: 5240-52 (2005)
National Taiwan University
09/26/06
-
Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.

J Med Chem 49: 5154-61 (2006)
National Defense Medical Center
09/26/06
-
Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.

J Med Chem 48: 4469-73 (2005)
National Taiwan University
09/26/06
-
Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.

J Med Chem 49: 4971-80 (2006)
TaiGen Biotechnology Co.
09/23/06